Insights & news

Four-Country Inclusive Vaccine Alliance Concludes Agreement with AstraZeneca for Supply of Possibly 400 Million Covid-19 Vaccines

  • 15/06/2020
  • Articles

The government of The Netherlands announced on 13 June 2020 that the Inclusive Vaccine Alliance (IVA) entered into a cooperation agreement with AstraZeneca for the supply of a possible vaccine against Covid-19 (see, attached letter to lower house of Parliament of Hugo de Jonge, the Dutch Minister for Public Health, Wellbeing and Sports and press-release). The IVA is a joint initiative of France, Germany, Italy and The Netherlands to secure a Covid-19 vaccine for the European Union and other countries as quickly as possible (see, Van Bael & Bellis Life Sciences News Alert of 4 June 2020).
The vaccine is still being developed by AstraZeneca and the University of Oxford. A clinical trial involving 10,000 test persons has just begun. A further trial involving 30,000 participants is scheduled to start at the end of June 2020. If the tests are successful and if the vaccine obtains a marketing authorisation from the European Medicines Agency, Minister de Jonge maintains that a first batch of vaccines might be available at the end of 2020. While the vaccine is under development and the outcome of this venture is still uncertain, the production of the vaccine is already in its preparatory stages.
The agreement with AstraZeneca provides for the initial supply of 300 million vaccines and a possible additional supply of 100 million doses. It is apparently not exclusive and the IVA will continue to talk with other vaccine developers as well.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *